Balance Sheet
Cash Flow Statement
Cash from Discontinued OperationsCash from Discontinued OperationsCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Cash from Operations (2019 - 2025)

Addex Therapeutics' Cash from Operations history spans 7 years, with the latest figure at 723169897008.2 for Q2 2025.

  • On a quarterly basis, Cash from Operations fell 70.2% to 723169897008.2 in Q2 2025 year-over-year; TTM through Jun 2025 was 10608431455.88, a 100.19% decrease, with the full-year FY2025 number at 2618646.08, up 57.31% from a year prior.
  • Cash from Operations came in at 723169897008.2 for Q2 2025, up from 665911069265.99 in the prior quarter.
  • The five-year high for Cash from Operations was 8307903520167.39 in Q4 2023, with the low at 6175000729211.9 in Q3 2024.
  • Historically, Cash from Operations has averaged 1739934186.59 across 5 years, with a median of 3191170.07 in 2021.
  • Biggest five-year swings in Cash from Operations: surged 260549967.07% in 2023 and later crashed 98554399.5% in 2024.
  • Year by year, Cash from Operations stood at 3193736.13 in 2021, then rose by 0.16% to 3188604.01 in 2022, then skyrocketed by 260549967.07% to 8307903520167.39 in 2023, then dropped by 26.49% to 6107133470013.81 in 2024, then crashed by 88.16% to 723169897008.2 in 2025.
  • Business Quant data shows Cash from Operations for ADXN at 723169897008.2 in Q2 2025, 665911069265.99 in Q1 2025, and 6107133470013.81 in Q4 2024.